V

Vistin Pharma ASA
OSE:VISTN

Watchlist Manager
Vistin Pharma ASA
OSE:VISTN
Watchlist
Price: 23.4 NOK Market Closed
Market Cap: 1B NOK
Have any thoughts about
Vistin Pharma ASA?
Write Note

Vistin Pharma ASA
Income from Continuing Operations

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Vistin Pharma ASA
Income from Continuing Operations Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Income from Continuing Operations CAGR 3Y CAGR 5Y CAGR 10Y
V
Vistin Pharma ASA
OSE:VISTN
Income from Continuing Operations
kr61.4m
CAGR 3-Years
32%
CAGR 5-Years
76%
CAGR 10-Years
N/A
Photocure ASA
OSE:PHO
Income from Continuing Operations
kr14.2m
CAGR 3-Years
24%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
N
Navamedic ASA
OSE:NAVA
Income from Continuing Operations
kr24.6m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
S
SoftOx Solutions AS
OSE:SOFTX
Income from Continuing Operations
-kr86.3m
CAGR 3-Years
-5%
CAGR 5-Years
-39%
CAGR 10-Years
N/A
No Stocks Found

Vistin Pharma ASA
Glance View

Market Cap
1B NOK
Industry
Pharmaceuticals

Vistin Pharma ASA engages in the manufacture and sale of metformin products. The company is headquartered in Oslo, Oslo. The company went IPO on 2015-06-10. The company was created as a result of spin-off of Weifa AS. The company specializes in manufacture of Active Pharmaceutical Ingredients (API) and Solid Dosage Forms. Its products portfolio is comprised of Metformin, Pholcodine and Codeine Phosphate, among others. The firm's products are sold domestically and abroad, including markets in Asia, America, Africa and Europe.

VISTN Intrinsic Value
22.56 NOK
Overvaluation 4%
Intrinsic Value
Price
V

See Also

What is Vistin Pharma ASA's Income from Continuing Operations?
Income from Continuing Operations
61.4m NOK

Based on the financial report for Sep 30, 2024, Vistin Pharma ASA's Income from Continuing Operations amounts to 61.4m NOK.

What is Vistin Pharma ASA's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 5Y
76%

Over the last year, the Income from Continuing Operations growth was 38%. The average annual Income from Continuing Operations growth rates for Vistin Pharma ASA have been 32% over the past three years , 76% over the past five years .

Back to Top